6 results match your criteria: "Royal Brompton Hospital and Harefield Trust[Affiliation]"
Lancet Reg Health Eur
March 2022
Cardiology and Aortic Centre, Royal Brompton Hospital and Harefield Trust, Sydney Street, London SW3 6NP, UK.
Heart
June 2020
Cardiology, Royal Brompton Hospital and Harefield Trust, London, UK.
Heart
November 2018
Cardiology and Aortic Centre, Royal Brompton Hospital and Harefield Trust, London, UK.
JACC Cardiovasc Interv
April 2018
Imperial College London and Hammersmith Hospital NHS Trust, London, United Kingdom. Electronic address:
Objectives: The authors sought to evaluate the accuracy of instantaneous wave-Free Ratio (iFR) pullback measurements to predict post-percutaneous coronary intervention (PCI) physiological outcomes, and to quantify how often iFR pullback alters PCI strategy in real-world clinical settings.
Background: In tandem and diffuse disease, offline analysis of continuous iFR pullback measurement has previously been demonstrated to accurately predict the physiological outcome of revascularization. However, the accuracy of the online analysis approach (iFR pullback) remains untested.
World J Cardiol
August 2017
Royal Brompton Hospital and Harefield Trust, London SW3 6NP, United Kingdom.
Research revealed that the pathogenesis of aortic stenosis (AS) not merely comprises of a mechanical wear and tear process yet that active biological processes, similar to those of coronary artery disease are involved, a promising role for statins in disease-modifying therapy was suggested. However, recently, many prospective studies could not observe decreased progression nor regression of the disease. Here, we review the current knowledge on the pathomechanisms of AS and its similarities and differences with atherosclerosis.
View Article and Find Full Text PDFPostepy Kardiol Interwencyjnej
July 2014
Cardiovascular Biomedical Research Unit, Royal Brompton Hospital and Harefield Trust, London, United Kingdom.
Fully bioresorbable vascular scaffolds (BVS) are a new approach to the percutaneous treatment of coronary artery disease. The BVS have not yet been fully tested in complex lesions, including chronic total occlusion (CTO). We report a CTO case successfully treated with a second-generation bioabsorbable drug-eluting scaffold.
View Article and Find Full Text PDF